Totus Medicines Stock

www.totusmedicines.comHealthcare / BioTech & PharmaFounded: 2020

Totus Medicines, founded in 2020, is a biotechnology research company whose Totus Platform strives to discover drugs for hard-to-treat diseases. Using a covalent molecule approach to identify undruggable targets, along with machine learning and sophisticated cellular examination, their platform aims to uncover drugs that can be used to treat advanced cancer conditions, heart disease, and brain degeneration. Totus has also developed a pipeline of oncology initiatives that are designed put cancer treatment at the forefront. Totus Medicines is headquartered in Emeryville, California.

Register To Buy and Sell Shares

For more details on financing and valuation for Totus Medicines, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Totus Medicines’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Totus Medicines.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Totus Medicines investors also invested in these private companies

Team

Management Team

Daisy Chhokar
Chief People Officer
Neil Dhawan Ph.D
Co-Founder, Head of Research and Development & Chief Scientific Officer
Tom Knudsen
Chief Business Officer
Jimmy Blair Ph.D
Co-Founder & Vice President of Platform Innovation Chemical Biology
Jason Pontin
Co-Founder
Ovid Trifan MD
Chief Medical Officer
Nassim Usman Ph.D
Chief Executive Officer & President
John Davies Ph.D
Chief Data Officer

Board Members

Ali Farahanchi
DHVC
Connor McDermott
Northpond Ventures
John Hamer Ph.D
DCVC Bio
Kiersten Stead Ph.D
DCVC Bio
Steve Liapis Ph.D
Northpond Ventures

Frequently Asked Questions About Totus Medicines’ Stock

plusminus
Can you buy Totus Medicines’ stock?
Totus Medicines is not publicly traded on NYSE or NASDAQ in the U.S. To buy Totus Medicines’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Totus Medicines’ stock?
Yes, you can sell stock of a private company like Totus Medicines. Forge can help you sell your Totus Medicines stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Totus Medicines’ stock price?
Totus Medicines is a privately held company and therefore does not have a public stock price. However, you may access Totus Medicines’ private market stock price with Forge Data.
plusminus
What is Totus Medicines’ stock ticker symbol?
Totus Medicines does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Totus Medicines Closes $66M Series B Funding
Totus Medicines, an Emeryville, CA-based small molecule drug discovery and development company using covalent libraries and AI tools, closed a $66M Series B financing. The round was led by DCVC Bio with participation from North Pond Ventures, Camford Capital, and the Regents of the University of Minnesota. Proceeds from the Series B financing will be used to advance Totus’ clinical program, expand the pipeline, and evolve the platform.
Updated on: Feb 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.